Related Experiment Video

Updated: Jun 13, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

[New therapeutics strategies in renal cell carcinoma]

J-B Meric1, B Billemont, O Rixe

  • 1Centre médical de Bligny, Département d'oncohématologie, 91640 Briis-sous-Forges, France. jb.meric@cm-bligny.com

Bulletin Du Cancer
|April 27, 2010
PubMed

Insights

New treatments for advanced renal cell carcinoma show promise by targeting specific molecular pathways. Future drug development focuses on novel anti-angiogenics and immunotherapies to improve patient survival and reduce toxicity.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Context:

  • Advanced renal cell carcinoma (RCC) treatment has evolved with molecularly targeted therapies.
  • Current anti-angiogenic drugs show limitations in overall survival and toxicity.
  • Clear cell carcinoma exhibits distinct molecular features like von Hippel-Lindau alterations and high immunogenicity.

Purpose:

  • To review future directions in drug development for advanced renal cell carcinoma.
  • To explore novel therapeutic strategies based on cellular and extracellular pathway interactions.
  • To highlight the potential of next-generation anti-angiogenics and immunotherapies.

Summary:

  • Recent advances in oncology offer new strategies for advanced renal cell carcinoma (RCC).
  • Molecular targeted therapies, including anti-angiogenics, have limitations.
  • Future drug development will focus on specific molecular pathways, including HIF, Notch, and angiopoietin inhibition.
  • Immunotherapy advancements offer new avenues for treating advanced RCC.

Impact:

  • Novel therapeutic approaches may improve the prognosis of advanced renal cell carcinoma.
  • Targeting specific molecular pathways could lead to more effective and less toxic treatments.
  • Understanding the immunogenicity profile of clear cell carcinoma is crucial for developing effective immunotherapies.

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...